Milbank LLP has advised the life science group Sartorius on its agreement to acquire MatTek Corp. and Visikol Inc. from BICO Group AB. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close during the second quarter of 2025.
Sartorius, headquartered in Göttingen, Germany, is a leading international partner of life science research and the biopharmaceutical industry. With approximately 60 manufacturing and sales sites worldwide, the company has a strong global presence. Sartorius regularly expands its portfolio by acquiring complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros and employed approximately 13,500 people globally.
MatTek, headquartered in Ashland, Massachusetts, is a leading developer and manufacturer of 3D microtissue models. Founded in 1985, the company employs more than 80 people at its headquarters in the US and its production site in Bratislava, Slovakia.
The Milbank team that advised Sartorius on the legal aspects of the transaction was co-led by partners Michael Bernhardt (Corporate/M&A, Frankfurt) and Dean W. Sattler (Corporate/M&A, New York).
The team also included partners Max Goodman (Tax, New York), and Alexander Rinne (Antitrust, Munich), as well as special counsel John Garces (Corporate/M&A, New York). Additional team members included associates Steffen Post (Corporate/M&A, Frankfurt), Stephanie Winkler (Corporate/M&A, New York), Frank Pensabene (Corporate/M&A, New York), Maximilian Müller (Corporate/M&A, Munich), Abigail King (Corporate/M&A, New York), Hendrik Gaebler (Corporate/M&A, Frankfurt), Jesse Hong (Tax, New York), Julia Roehrer (Antitrust, Munich), and Miriam Arimond (Finance, Frankfurt).
The Sartorius in-house legal team was led by General Counsel Jens M. Artelt.
